Form D · Biotechnology
E25Bio Inc.
Cambridge, MA · CIK 0001786210
Offering snapshot reported Jun 1, 2021 · SEC filing
- Reported sold
- $500K Offering amount: $500K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 17, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 1, 2021 | Initial | $500,000 | No comparison | 1 | SEC filing |
| May 19, 2020 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Mar 26, 2020 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Aug 22, 2019 | Initial | $2,299,970 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-401199
Source: Form D, filed Jun 1, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Irene Bosch | Director, Executive |
| Prashant Chouta | Director, Executive |
| Ann De Witt | Director |
| Shadah Enrique | Executive |
| Bobby Herrara | Executive |
| Bobby Brooke Herrera | Executive |
| Jeff Takle | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
501 Massachusetts Avenue, Office 221
Cambridge, MA, 02139
Cambridge, MA, 02139